Golimumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06674 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 29 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | rheumatoid vasculitis | KG + DL |
| 2 | hypermobility of coccyx | KG + DL |
| 3 | inflammatory spondylopathy | KG + DL |
| 4 | Kummell disease | KG + DL |
| 5 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 6 | vertebral disease | KG + DL |
| 7 | congenital hypotrichosis with juvenile macular dystrophy | KG + DL |
| 8 | polyp of vocal cord | KG + DL |
| 9 | polyp of middle ear | KG + DL |
| 10 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 11 | polyp of ureter | KG + DL |
| 12 | polyp of frontal sinus | KG + DL |
| 13 | epulis | KG + DL |
| 14 | polyp of external auditory canal | KG + DL |
| 15 | uterine polyp | KG + DL |
| 16 | polyp of vulva | KG + DL |
| 17 | heparin cofactor 2 deficiency | KG + DL |
| 18 | fibroepithelial polyp | KG + DL |
| 19 | neoplastic polyp | KG + DL |
| 20 | antithrombin deficiency type 2 | KG + DL |
| 21 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 22 | anus disease | KG + DL |
| 23 | functional neutrophil defect | KG + DL |
| 24 | granulomatous disease, chronic, autosomal recessive, 5 | KG + DL |
| 25 | granulomatous disease with defect in neutrophil chemotaxis | KG + DL |
| 26 | Crohn disease of the esophagus | KG + DL |
| 27 | seborrheic dermatitis | KG + DL |
| 28 | brachydactyly-syndactyly syndrome | KG + DL |
| 29 | acne (disease) | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.